Neuroendocrine tumours: trials for referral
262 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Neuroendocrine tumours·What we know·Glossary·Tumour board sheet
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
262 trials shown
Phase 21 site
RecruitingUnited States
NCT06406465
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
National Cancer Institute (NCI)
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 285 sites
RecruitingAustralia, Canada, Chile, China, Germany, Denmark
NCT04924075
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Merck Sharp & Dohme LLC
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 3169 sites
RecruitingArgentina, Austria, Australia, Belgium, Brazil, Canada
NCT07544654
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
Boehringer Ingelheim
Pre-treatment window Registry sentence: “No prior systemic treatment for unresectable locally advanced or metastatic epNEC (except for the completed one cycle of standard platinum + etoposide).”
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT01174121
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
National Cancer Institute (NCI)
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT06041516
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
National Cancer Institute (NCI)
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 22 sites
RecruitingUnited States
NCT07684170
Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms
Compass Therapeutics
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 2/3266 sites
RecruitingUnited States
NCT05058651
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
National Cancer Institute (NCI)
Pre-treatment window Registry sentence: “Participants with treatment-naive brain lesions must have:”
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 32 sites
RecruitingUnited States
NCT07842172
Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms
Washington University School of Medicine
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 229 sites
RecruitingUnited States
NCT04665739
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
National Cancer Institute (NCI)
Pre-treatment window Registry sentence: “REGISTRATION: Patients with treatment-naive or previously-treated disease are allowed.”
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT06176989
Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
National Cancer Institute (NCI)
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 2582 sites
RecruitingPuerto Rico, United States
NCT03866382
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
Pre-treatment window Registry sentence: “Other miscellaneous histologic variants of the urothelial carcinoma, such as, but not limited to (Cohort G) : Micropapillary (Tumor should show predominantly \> or equal 50% micropapillary architecture), giant cell, lipid-rich, clear cell and nested variants (Tumor should predominantly \> or equal 50% show these features), large cell neuroendocrine carcinoma, lymphoepithelioma-like carcinoma and mixed patterns will be considered, as well as small cell neuroendocrine prostate cancer (Only treatment-naïve primary small cell of prostate with any amount of small cell component allowed.”
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 17 sites
Not yet recruitingUnited States
NCT06941480
A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate
Memorial Sloan Kettering Cancer Center
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 213 sites
RecruitingUnited States
NCT05691465
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
National Cancer Institute (NCI)
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 243 sites
RecruitingCanada, United States
NCT05773274
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
National Cancer Institute (NCI)
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 114 sites
RecruitingCanada, United States
NCT07165132
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
RayzeBio, Inc.
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 30 sites
Not yet recruiting
NCT07910760
TRINITY TRIAL; Trial Of PRRT Plus CAPTEM Vs CAPTEM Alone In Well Differentiated GEP NETS
Tata Memorial Hospital
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingChina
NCT06505824
A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
Biokin (Shanghai) Biopharmaceutical Co., Ltd.
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT03412877
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Cancer Institute (NCI)
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 2/3135 sites
RecruitingAustria, Australia, Belgium, Brazil, Canada, China
NCT06943755
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Exelixis
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 131 sites
RecruitingGeorgia, Ukraine, United States
NCT07080242
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
SystImmune Inc.
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT07509034
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease
National Cancer Institute (NCI)
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 34 sites
By invitation onlyUnited States
NCT07620574
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Exelixis
Registry updated 28 Oct 2026
Registry record: ClinicalTrials.govPhase 1/226 sites
Not yet recruitingAustralia, Belgium, China, Germany, Spain, France
NCT07707895
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
Boehringer Ingelheim
Pre-treatment window Registry sentence: “Patients must have received no prior systemic therapy for ES-SCLC.”
Registry updated 27 Oct 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT03206060
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
National Cancer Institute (NCI)
Pre-treatment window Registry sentence: “NOTE: Untreated participants with existing histologic diagnoses are eligible if progression can be demonstrated”
Registry updated 26 Oct 2026
Registry record: ClinicalTrials.govPhase 30 sites
Not yet recruiting
NCT07894211
QLC5508 vs. Investigator's Choice Chemotherapy in Advanced Extrapulmonary Neuroendocrine Carcinoma
Qilu Pharmaceutical Co., Ltd.
Registry updated 26 Oct 2026
Registry record: ClinicalTrials.govPhase 17 sites
RecruitingUnited States
NCT07783477
A Study of Armored CAR T Cells in People With Cancer
Memorial Sloan Kettering Cancer Center
Registry updated 22 Oct 2026
Registry record: ClinicalTrials.govPhase 10 sites
Not yet recruiting
NCT07890246
A Phase 1 Study of IM-1340 in Participants With Advanced Cancer
Immunome, Inc.
Registry updated 22 Oct 2026
Registry record: ClinicalTrials.govPhase 1/28 sites
RecruitingUnited States
NCT07278479
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Molecular Partners AG
Registry updated 21 Oct 2026
Registry record: ClinicalTrials.govPhase 21 site
Not yet recruitingUnited States
NCT06202066
Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas
Roswell Park Cancer Institute
Registry updated 20 Oct 2026
Registry record: ClinicalTrials.govPhase 110 sites
RecruitingCanada, United States
NCT05687123
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Pre-treatment window Registry sentence: “Patients may be treatment naïve or have disease progression on or intolerance of up to one line of systemic therapy other than somatostatin analog therapy (somatostatin analog therapy is not considered a line of systemic therapy).”
Registry updated 20 Oct 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- United States89 open trials
- China62 open trials
- France40 open trials
- Italy25 open trials
- Spain16 open trials
- Canada16 open trials
- Germany14 open trials
- Netherlands13 open trials
- Poland12 open trials
- Australia10 open trials
- South Korea9 open trials
- Belgium8 open trials
- United Kingdom7 open trials
- Denmark7 open trials
- Japan6 open trials
- Brazil6 open trials
- Sweden5 open trials
- Taiwan5 open trials
- Hungary4 open trials
- Portugal4 open trials
- Mexico4 open trials
- Norway3 open trials
- Czechia3 open trials
- Austria3 open trials
- Puerto Rico3 open trials
- India3 open trials
- Switzerland3 open trials
- Chile2 open trials
- Israel2 open trials
- Argentina2 open trials
- Finland2 open trials
- Greece2 open trials
- Russia1 open trial
- Türkiye1 open trial
- Singapore1 open trial
- Hong Kong1 open trial
- Georgia1 open trial
- Ukraine1 open trial
- Bulgaria1 open trial
- Réunion1 open trial
- Peru1 open trial
- New Zealand1 open trial
- Saudi Arabia1 open trial
- Romania1 open trial
- Egypt1 open trial
- Algeria1 open trial
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Bologna, Italy
1 trial · 13 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
Opened for recruitment
PET/CT Imaging Study With Simultaneous Dual-nuclide Imaging Technique
NCT06914427 · No phase · China
Source: ClinicalTrials.govPhase changed: No phase → Phase 1/2
Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, BTC or NEN
NCT06735560 · Phase 1/2 · France
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
NCT07707895 · Phase 1/2 · Australia, Belgium, China, Germany, Spain, France
Source: ClinicalTrials.govOpened for recruitment
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
NCT07174583 · Phase 1/2 · Spain, France, United States
Source: ClinicalTrials.govOpened for recruitment
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
NCT07006727 · Phase 1 · Canada, Germany, Spain, France, Italy, Japan
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy
NCT02749331 · Phase 1/2 · Sweden
Source: ClinicalTrials.govPhase changed: Phase 1 → Phase 1/2
Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy
NCT02749331 · Phase 1/2 · Sweden
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
NCT07174583 · Phase 1/2 · Spain, France, United States
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
NCT07006727 · Phase 1 · Canada, Germany, Spain, France, Italy, Japan
Source: ClinicalTrials.govOpened for recruitment
NCT07707895 · Phase 1/2 · Australia, Belgium, China, Germany, Spain, France
Source: ClinicalTrials.gov
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
Phase 2Ended 3 Sept 2026
Stopped early1 participant
NCT07061080
Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab
Reason given: AMGEN, due to a change in priorities within the Tarlatamab programme, has decided to withdraw its support for the study, which means the clinical trial will be terminated early.
Phase 1/2Ended 24 Aug 2026
Stopped early634 participants
NCT03145857
A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use
Reason given: The market approved 68Ga-DOTATATE (NETSPOT(R)) is now approved for public funding in Alberta and is considered standard of care. Furthermore, the manufacturer of the study Investigational Product (IP) is no longer supplying the IP.
No phaseEnded 18 Aug 2026
Completed195 participants
NCT02743741
Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors
- Cumulative Absorbed Dose and Successive Cyclic Reduction in Absorbed Dose Predict Response to 177Lu-DOTATATE in Neuroendocrine Tumors. · Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026
No phaseEnded 1 Jul 2026
Phase 2Ended 9 Jun 2026
Stopped early6 participants
NCT06158516
A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors
Reason given: This investigator-initiated study closed to recruitment early due to slower-than-anticipated patient accrual.
No phaseEnded 1 Jun 2026
Phase 1Ended 31 May 2026
Phase 2Ended 31 May 2026
Completed32 participants
NCT03457948
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases
Phase 2Ended 18 May 2026
Completed45 participants
NCT04524208
CABONEN – a phase II trial of Cabozantinib in patients with advanced, low proliferative NEN G3
Phase 2Ended 30 Apr 2026
Completed14 participants
NCT04010357
Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC
Phase 1/2Ended 25 Apr 2026
Withdrawn before start0 participants
NCT07328490
Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer
Reason given: Study drug supplier withdrew support; no participants were enrolled.
No phaseEnded 23 Mar 2026
Completed72 participants
NCT05461430
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
No phaseEnded 10 Mar 2026
Completed164 participants
NCT04727723
Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs
Phase 2Ended 24 Feb 2026
Completed36 participants
NCT05361668
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Phase 1Ended 9 Feb 2026
Completed83 participants
NCT02402920
Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer
Phase 2Ended 2 Feb 2026
Stopped early11 participants
NCT04754425
Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer
Reason given: \<75% participation
Phase 1Ended 31 Dec 2025
Completed6 participants
NCT05475210
177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors
Phase 2Ended 2 Dec 2025
Completed55 participants
NCT03728361
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
Phase 3Ended 27 Nov 2025
Completed69 participants
NCT06091748
Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors
Phase 1Ended 27 Oct 2025
Completed15 participants
NCT05262556
NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas
Show more
Phase 2Ended 21 Oct 2025
Stopped early1 participant
NCT05987176
Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases
Reason given: The study has closed earlier than planned due to one of the funders decision to withdraw the financial support for the study.
Phase 2Ended 15 Oct 2025
Stopped early14 participants
NCT04042714
TAS-102 in Extrapulmonary Neuroendocrine Carcinoma
Reason given: Study halted due to low enrollment
Phase 2Ended 3 Oct 2025
Phase 1Ended 1 Sept 2025
No phaseEnded 31 Aug 2025
Stopped early1245 participants
NCT01039922
SwissNET - a Registry for Neuroendocrine Tumours in Switzerland
Reason given: The register will no longer be maintained on a prospective basis
Phase 1/2Ended 31 Aug 2025
Phase 2Ended 23 Jul 2025
Stopped early20 participants
NCT05420636
Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET
Reason given: Closed to accrual due to low probability of successful outcomes
Phase 1Ended 23 Jul 2025
Completed33 participants
NCT05411133
Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients
No phaseEnded 19 Jul 2025
Phase 1Ended 18 Jul 2025
Phase 1/2Ended 1 Jul 2025
Completed316 participants
NCT02611024
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
- Combination of Lurbinectedin Plus Irinotecan: Preclinical and Early Clinical Results in Patients With Relapsed SCLC. · Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2026
No phaseEnded 2 Jun 2025
Completed30 participants
NCT04069299
Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract
Phase 2Ended 30 Apr 2025
Withdrawn before start0 participants
NCT05582031
Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers
Reason given: Study never started/ will not proceed.
No phaseEnded 29 Apr 2025
Completed20 participants
NCT05017662
A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072
No phaseEnded 29 Mar 2025
Completed633 participants
NCT06983106
Correlation Between Body Composition and Pathologic Grade/Prognosis in GEP-NENs: A Retrospective Study
Phase 1/2Ended 17 Mar 2025
Phase 1Ended 14 Mar 2025
Completed19 participants
NCT03879694
Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors
Phase 1Ended 4 Mar 2025
No phaseEnded 11 Feb 2025
Completed50 participants
NCT05246319
Preoperative Imaging in Patients With Small Bowel Neuroendocrine Tumors
No phaseEnded 27 Jan 2025
Completed71 participants
NCT04696042
Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs
Phase 1/2Ended 17 Jan 2025
Early Phase 1Ended 31 Dec 2024
Completed32 participants
NCT04510311
Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors
No phaseEnded 30 Dec 2024
Completed32 participants
NCT05013957
Neuroendocrine Neoplasms Methylation Based Classifier - The NEMESIs-study
Phase 1/2Ended 26 Dec 2024
Completed62 participants
NCT02487095
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers
- Plasma nucleosome profiling reports on tumor burden and molecular subtypes in small cell lung cancer. · The Journal of clinical investigation, 2026
Phase 2Ended 15 Dec 2024
Completed185 participants
NCT03591731
Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)
- Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026
No phaseEnded 6 Dec 2024
Completed20 participants
NCT06253897
A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly
Phase 1Ended Nov 2024
Stopped early7 participants
NCT02464007
Study of rSIFN-co for Patients With Advanced Solid Tumors
Reason given: Protocol has been amended and the Protocol amendment of Phase II was approved by the US FDA on Nov 2024 through SN0028.
Phase 2Ended 26 Nov 2024
Completed58 participants
NCT03837977
Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma
Phase 2Ended 26 Nov 2024
Completed45 participants
NCT04438304
A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)
Phase 2Ended 11 Nov 2024
Stopped early11 participants
NCT05568017
Neoadjuvant PRRT With Y-90-DOTATOC in pNET
Reason given: Difficulty in recruiting patients also due to the pandemic period, presence of competitive studies.
No phaseEnded 11 Nov 2024
Completed50 participants
NCT06790056
Efficacy of Endoscopic Band Ligation (DEBL) for Duodenal Neuroendocrine Neoplasms(dNENs)
Phase 2Ended 8 Nov 2024
Completed162 participants
NCT02724540
Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver
No phaseEnded 31 Oct 2024
Completed167 participants
NCT04028479
The Registry of Oncology Outcomes Associated With Testing and Treatment
Phase 2Ended 15 Oct 2024
Stopped early78 participants
NCT04579679
Open-Label Surufatinib in European Patients With NET
Reason given: Sponsor decision
Phase 2Ended 30 Sept 2024
Completed79 participants
NCT04705519
Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine Carcinoma
Phase 1/2Ended 11 Sept 2024
Withdrawn before start0 participants
NCT05610826
Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver
Reason given: 0 enrollment
No phaseEnded 1 Sept 2024
No phaseEnded 31 Aug 2024
Completed230 participants
NCT06024343
Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Exposure, Repair or Reconstruction
Phase 1/2Ended 27 Aug 2024
Stopped early87 participants
NCT04579757
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Reason given: Study terminated by sponsor
Phase 2Ended 26 Aug 2024
Stopped early11 participants
NCT03736720
Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin
Reason given: low accrual
Not medical advice. fetched 11 Nov 2026